Source comparison
Sermorelin for Men 45-55 Andropause: Dosing and Protocol Comparison
Low-Dose Monotherapy 200-300 mcg Daily Bedtime (30 min before sleep) 15-25% above baseline at 12 weeks Entry protocol for men with mild symptoms; preserves pituitary sensitivity Standard Therapeutic Dose 500-750 mcg Bedtime 30-45% above baseline at 12 weeks Mo
This comparison does not assign a generated winner or score.
- Low-Dose Monotherapy
- 200-300 mcg
- Daily
- Bedtime (30 min before sleep)
- 15-25% above baseline at 12 weeks
- Entry protocol for men with mild symptoms; preserves pituitary sensitivity
- Standard Therapeutic Dose
- 500-750 mcg
- Bedtime
- 30-45% above baseline at 12 weeks
- Most common clinical dose; balances efficacy and cost; used in published andropause studies
- High-Dose Protocol
- 1000-1500 mcg
- Daily or 5 days/week
- 50-70% above baseline at 12 weeks
- Reserved for non-responders or severe GH deficiency; higher cost, diminishing returns above 1000 mcg
- Pulsed Dosing (Mimic Physiological Pattern)
- 300 mcg
- Twice daily (morning + bedtime)
- Pre-breakfast and pre-sleep
- 35-50% above baseline at 12 weeks
- Mimics natural pulsatile release; requires more frequent injection; used in research settings
- Professional Assessment
- Sermorelin works best when pituitary function is intact. Men with pituitary adenomas, poorly controlled diabetes, or active malignancy are not candidates. Dosing should be titrated based on IGF-1 response measured at 6-week intervals. Non-responders at 12 weeks should stop rather than escalate indefinitely.